摘要
目的分析奥美拉唑肠溶胶囊联合复合凝乳酶胶囊治疗功能性消化不良患儿的临床疗效。方法采用回顾性研究,选择2020年8月~2021年6月于武汉儿童医院消化科就诊的150例功能性消化不良患儿作为研究对象,根据治疗方法的不同将患儿分为2组,对照组(80例)采用0.6~1.0 mg·kg^(-1)奥美拉唑肠溶胶囊治疗,试验组(70例)采用0.6~1.0 mg·kg^(-1)奥美拉唑肠溶胶囊联合复合凝乳酶胶囊(1~2粒)治疗,2组均连续治疗2周,评估2组患儿的临床疗效及症状积分,记录2组患儿的症状缓解时间及药物不良反应发生情况。结果治疗后,试验组和对照组患儿的总有效率分别为90.00%与76.25%;餐后饱胀症状积分分别为(0.66±0.17)与(0.82±0.16)分;早饱症状积分分别为(0.71±0.22)与(0.87±0.16)分;腹痛症状积分分别为(0.51±0.10)与(0.62±0.14)分;腹胀症状积分分别为(0.48±0.14)与(0.67±0.22)分;上腹烧灼感症状积分分别为(0.86±0.23)与(1.09±0.26)分;大便性状恢复时间分别为(4.69±0.78)与(5.42±0.54)d;排便次数减少时间分别为(3.39±0.63)与(4.21±0.72)d;腹胀腹痛消失时间分别为(3.58±0.52)与(5.64±0.81)d;上述指标组间对比,差异均有统计学意义(均P<0.05)。试验组和对照组患儿的药物不良反应发生率分别为20.00%和10.00%,差异无统计学意义(P>0.05)。结论奥美拉唑肠溶胶囊联合复合凝乳酶胶囊治疗功能性消化不良患儿的疗效显著,可有效改善临床症状,安全性较高。
Objective To analyze the clinical efficacy of omeprazole enteric-coated capsules combined with compound rennet capsules in the treatment of children with functional dyspepsia.Methods The trial was conducted by retrospective study.A total of 150 children with functional dyspepsia who were treated in the Department of Gastroenterology,Wuhan Children’s Hospital from August 2020 to June 2021 were selected as subjects.According to different treatment methods,the children were divided into two groups.The control group(80 cases)was treated with 0.6-1.0 mg·kg^(-1)omeprazole enteric-coated capsules,and the treatment group(70 cases)was treated with 0.6-1.0 mg·kg^(-1)omeprazole enteric-coated capsules combined with compound rennet capsules(1-2 capsules).The clinical efficacy and symptom scores of the two groups were evaluated,and the symptom relief time and adversedrug reactions of the two groups were recorded.Results After treatment,the total effective rate of the treatment group and control group was 90.00%and 76.25%,respectively.The scores of postprandial fullness symptom in treatment group and control group were(0.66±0.17)and(0.82±0.16)points,respectively.The scores of early satiety symptoms in treatment group and control group were(0.71±0.22)and(0.87±0.16)points,respectively.The scores of epigastric pain in treatment group and control group were(0.51±0.10)and(0.62±0.14)points,respectively.The abdominal distension symptom score of treatment group and control group was(0.48±0.14)and(0.67±0.22)points,respectively.The score of upper abdominal burning symptom in treatment group and control group was(0.86±0.23)and(1.09±0.26)points,respectively.The recovery time of stool traits in treatment group and control group was(4.69±0.78)and(5.42±0.54)d,respectively.The reduction time of defecation frequency in treatment group and control group was(3.39±0.63)and(4.21±0.72)d,respectively.The disappearance time of abdominal distention and abdominal pain in treatment group and control group was(3.58±0.52)and(5.64±0.81)
作者
王丹
孟玲玲
彭罕鸣
WANG Dan;MENG Ling-ling;PENG Han-ming(Department of Gastroenterology,Wuhan Children's Hospital,Tongji Medical College,Huazhong University of Science and Technology(Wuhan Maternal and Child Health Hospital),Wuhan 430015,Hubei Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2022年第20期2411-2414,共4页
The Chinese Journal of Clinical Pharmacology
基金
武汉市卫生健康委员会科研基金资助项目(WX21Q67)。
关键词
奥美拉唑肠溶胶囊
复合凝乳酶胶囊
功能性消化不良
临床症状积分
腹胀
omeprazole enteric-coated capsules
compound rennet capsule
functional dyspepsia
clinical symptom score
ventosity
